Educational Objectives:
- Discuss the mechanisms of action of the new and emerging medications and the novel medication targets within the trabecular meshwork (TM)
- Evaluate the clinical trials results of newly approved ocular hypotensive agents, including ROCK inhibitors and combination agents
- Review strategies for setting patient expectations and improving patient compliance with glaucoma therapy
Chair and Moderator:
Leon W. Herndon Jr., MD
Professor of Ophthalmology
Chief, Glaucoma Division
Duke Eye Center
Durham, NC
Speaker:
Arthur J. Sit, MD
Professor of Ophthalmology
Vice Chair, Clinical Practice
Glaucoma Fellowship Director
Department of Ophthalmology
Mayo Clinic
Rochester, MN